Legal

• Approaches to Algorithm Protection in China, from the Perspectives of Trade Secrets and Patents

  Partner Xiangxiang Ma of Anjie Broad Law Firm examines the advantages and disadvantages of two key approaches to the legal protection of vital AI algorithms

  April 16, 2025

  

• In the News: China Restricts Outbound Investments; Shenzhen Foreign Hospitals; and US Companies Survey

  China to block Chinese firms from investing in the U.S. amid tariff war; Shenzhen launches incentives for foreign-owned hospitals following national legislation; and U.S. companies plan continuous engagement with China

  April 11, 2025

  

• State Council, Provisions for Implementation of the «Anti-Foreign Sanctions Law»

  国务院实施«中华人民共和国反外国制裁法»的规定

  China specifies penalties for a failure to implement sanction countering measures / CLP Reference: 1300/25.03.23 ; Promulgated: 2025-03-23 ; Effective: 2025-03-23

  April 08, 2025

• Legislation roundup: Cybersecurity Law amendment draft, pharma clinical data and facial recognition

  Cybersecurity Law amendment draft imposes heavier penalties. China proposes different data protection periods for three categories of drugs. Facial information collection requires obligations of informing individuals.

  April 08, 2025

• State Council, Provisions for Handling Foreign-Related Intellectual Property Disputes

  国务院关于涉外知识产权纠纷处理的规定

  State Council restricts provision of evidence outside of mainland China for IP cases / CLP Reference: 5100/25.03.13 ; Promulgated: 2025-03-13 ; Effective: 2025-05-01

  April 08, 2025

• National Financial Regulatory Administration, Circular on Matters Relevant to the Acquisition by Hong Kong and Macao Financial Institutions of Equity Stakes in Insurance Companies

  国家金融监督管理总局关于香港、澳门金融机构入股保险公司有关事项的通知

  Total asset requirement is relaxed for Hong Kong and Macao insurance company investments / CLP Reference: 3910/25.02.26 ; Issued: 2025-02-26 ; Effective: 2025-03-01

  April 08, 2025

• In the News: Pharma Data Protection Rules; Facial Recognition Restrictions; and UBS Fully Owns Its Chinese Operations

  China’s draft pharmaceutical trial rules aim to balance innovation with drug availability; CAC issues first rules to regulate facial recognition technology; and UBS becomes the 5th wholly foreign-owned securities firm in China.

  April 03, 2025

  

• Illumina’s Inclusion in China’s Unreliable Entity List: Patent Wars, Geopolitical Risks, and Compliance Strategies

  Jianwei (Jerry) Fang, Xiaoyu (Arthur) Jin and Haoyi Sun of Zhong Lun Law Firm discuss the reasons behind, and the implications of, Illumina’s inclusion in China’s Unreliable Entity List, as well as compliance recommendations for multinational corporations

  April 02, 2025

  

• In the News: Anti-Foreign Sanctions Law Expands; Chinese Companies Shift Manufacturing Overseas; and China Pushes for IP Protections Abroad

  China strengthens Anti-Foreign Sanctions Law in response to U.S. restrictions; Chinese firms move production facilities overseas amidst key economic changes; and China introduces regulations to protect interests in overseas IP disputes

  March 28, 2025

  

• State-Owned Assets Supervision and Administration Commission of the State Council, Operational Rules for Transactions Involving State-Owned Assets of Enterprises

  国务院国有资产委员会企业国有资产交易操作规则

  New rules are set forth for capital increases of state-owned enterprises / CLP Reference: 2300/25.02.18 ; Issued: 2025-02-18 ; Effective: 2025-02-18

  March 27, 2025